Dogwood Therapeutics, Inc.
NCM: DWTXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Dogwood Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get DWTX Z-Score →About Dogwood Therapeutics, Inc.
Healthcare
Biotechnology
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2020 and is based in Alpharetta, Georgia.
📊 Fundamental Analysis
Dogwood Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -49.2%, which indicates that capital utilization is currently under pressure.
At a current price of $1.99, DWTX currently trades near the bottom of its 52-week range (3%), indicating potential value or weakness (Range: $1.77 - $9.50).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$66.26M
Trailing P/E
--
Forward P/E
-0.31
Beta (5Y)
2.07
52W High
$9.50
52W Low
$1.77
Avg Volume
54K
Day High
Day Low